Diploma Results Presentation Deck

21 Diploma PLC Half Year 2023 Results Life Sciences * % of Group revenue Sector revenue mix* O 44% 38% 18% Canada Europe Australia Pro forma revenues adjusted for acquisitions and disposals completed during the year 18% Revenue Organic growth Adjusted operating profit Adjusted operating margin H1 2023 highlights • 4% organic growth H1 2023 £105.6m +4% £20.9m 19.8% H1 2022 £87.1m -7% £19.6m 22.5% Momentum accelerating in Q2 Continued recovery in surgical and operating room procedures Normalising healthcare development investment post-pandemic - Strong diagnostic performance Well positioned for continued growth Elective surgical backlogs Rising diagnostics investment - Increasing funding approvals into medical equipment Change +21% +7% -270bps Margin -270bps: Accuscience first year acquisition dilution impact, lapped in H2. Mix: more capital this half / more consumable roll-off thereafter at higher margin DIPLOMA PLC

View entire presentation